CA2323809A1 - A method for chemoprevention of prostate cancer - Google Patents

A method for chemoprevention of prostate cancer Download PDF

Info

Publication number
CA2323809A1
CA2323809A1 CA002323809A CA2323809A CA2323809A1 CA 2323809 A1 CA2323809 A1 CA 2323809A1 CA 002323809 A CA002323809 A CA 002323809A CA 2323809 A CA2323809 A CA 2323809A CA 2323809 A1 CA2323809 A1 CA 2323809A1
Authority
CA
Canada
Prior art keywords
prostate cancer
prostate
chemoprevention
provides
toremifene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002323809A
Other languages
French (fr)
Other versions
CA2323809C (en
Inventor
Mitchell S. Steiner
Sharan Raghow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
The University Of Tennessee Research Corporation
Mitchell S. Steiner
Sharan Raghow
University Of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tennessee Research Corporation, Mitchell S. Steiner, Sharan Raghow, University Of Tennessee Research Foundation filed Critical The University Of Tennessee Research Corporation
Publication of CA2323809A1 publication Critical patent/CA2323809A1/en
Application granted granted Critical
Publication of CA2323809C publication Critical patent/CA2323809C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.
CA002323809A 1998-05-07 1999-05-07 A method for chemoprevention of prostate cancer Expired - Fee Related CA2323809C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8460298P 1998-05-07 1998-05-07
US60/084,602 1998-05-07
PCT/US1999/010146 WO1999056739A1 (en) 1998-05-07 1999-05-07 A method for chemoprevention of prostate cancer

Publications (2)

Publication Number Publication Date
CA2323809A1 true CA2323809A1 (en) 1999-11-11
CA2323809C CA2323809C (en) 2007-09-18

Family

ID=22186034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323809A Expired - Fee Related CA2323809C (en) 1998-05-07 1999-05-07 A method for chemoprevention of prostate cancer

Country Status (26)

Country Link
US (1) US6265448B1 (en)
EP (3) EP1003496B1 (en)
JP (2) JP4482229B2 (en)
AT (1) ATE283043T1 (en)
AU (1) AU761435B2 (en)
BG (1) BG65597B1 (en)
CA (1) CA2323809C (en)
CZ (1) CZ300960B6 (en)
DE (2) DE69922131T2 (en)
DK (1) DK1003496T3 (en)
EA (1) EA003466B1 (en)
ES (1) ES2145730T3 (en)
HR (1) HRP20000729A2 (en)
HU (1) HUP0102068A3 (en)
IL (3) IL138437A0 (en)
IS (2) IS2213B (en)
NO (1) NO20005625L (en)
NZ (1) NZ527522A (en)
PL (1) PL207462B1 (en)
PT (1) PT1003496E (en)
SI (1) SI1003496T1 (en)
SK (1) SK16642000A3 (en)
TR (1) TR200003269T2 (en)
UA (1) UA74532C2 (en)
WO (1) WO1999056739A1 (en)
YU (1) YU68600A (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1003496B1 (en) * 1998-05-07 2004-11-24 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
EP1214039A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
SI1666033T1 (en) 2001-11-29 2009-06-30 Gtx Inc Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US20050208159A1 (en) * 2004-03-16 2005-09-22 Kang Kyung S Phytoestrogenic composition comprising an extract of chinese licorice root, liquiritin or isoliquiritin
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
USD969722S1 (en) 2021-09-28 2022-11-15 Wagner Delima Stabilizing wedge pad

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
FI77839C (en) * 1982-05-27 1989-05-10 Farmos Oy FOERFARANDE FOER FRAMSTAELLNING AV NYA THERAPEUTIC EFFECTIVE TRIPHENYLALKAN- OCH ALKENDERIVAT.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
JPH08503848A (en) * 1992-12-01 1996-04-30 マイヤ ヴェリ、アニ Syndecan stimulation of cell differentiation
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
JPH08510451A (en) 1993-05-13 1996-11-05 ネオルックス コーポレイション Prevention and treatment of pathogenesis associated with hyperproliferative smooth muscle cells
US5788964A (en) 1993-08-09 1998-08-04 Orion-Yhtyma Oy Method for sensitization of cancer cells for killer cell mediated lysis
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
ZA984650B (en) * 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
EP1003496B1 (en) * 1998-05-07 2004-11-24 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia

Also Published As

Publication number Publication date
JP2002513755A (en) 2002-05-14
CA2323809C (en) 2007-09-18
BG105022A (en) 2001-07-31
UA74532C2 (en) 2006-01-16
WO1999056739A1 (en) 1999-11-11
IL193231A0 (en) 2009-02-11
EA200000100A1 (en) 2000-08-28
HRP20000729A2 (en) 2001-06-30
IS8354A (en) 2006-03-15
JP4482229B2 (en) 2010-06-16
HUP0102068A2 (en) 2002-05-29
ATE283043T1 (en) 2004-12-15
NO20005625D0 (en) 2000-11-07
DE69922131D1 (en) 2004-12-30
IL138437A (en) 2008-12-29
EP1003496A1 (en) 2000-05-31
HUP0102068A3 (en) 2002-11-28
PL344000A1 (en) 2001-09-10
EP1003496B1 (en) 2004-11-24
SI1003496T1 (en) 2005-10-31
CZ20004118A3 (en) 2002-07-17
EA003466B1 (en) 2003-06-26
NO20005625L (en) 2001-01-05
AU4072699A (en) 1999-11-23
PT1003496E (en) 2005-04-29
TR200003269T2 (en) 2001-02-21
SK16642000A3 (en) 2002-08-06
PL207462B1 (en) 2010-12-31
EP1475087A2 (en) 2004-11-10
ES2145730T1 (en) 2000-07-16
ES2145730T3 (en) 2005-06-16
JP2008163048A (en) 2008-07-17
BG65597B1 (en) 2009-02-27
DE1003496T1 (en) 2000-11-02
IL138437A0 (en) 2001-10-31
IS2213B (en) 2007-03-15
NZ527522A (en) 2005-04-29
YU68600A (en) 2003-12-31
DK1003496T3 (en) 2005-04-04
CZ300960B6 (en) 2009-09-23
EP1475087A3 (en) 2007-07-11
EP2277514A1 (en) 2011-01-26
US6265448B1 (en) 2001-07-24
AU761435B2 (en) 2003-06-05
IS5700A (en) 2000-11-01
DE69922131T2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
CA2323809A1 (en) A method for chemoprevention of prostate cancer
NO20022221L (en) A procedure for a chemical prevention of prostate cancer
Witting et al. A rapid and simple screening test for potential inhibitors of tocopherol-mediated peroxidation of LDL lipids
BR9916518A (en) A method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and a combination comprising a cyclooxygenase-2 inhibitor and one or more antineoplastic agents.
EA200000220A1 (en) COMBINATION OF TYROSINKINASE INHIBITOR AND CHEMICAL STERILIZATION FOR TREATMENT OF PROSTATE GLAND
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
BR9815171A (en) IV powder inhibiting compound applicable in the treatment of diseases, particularly asthma, in mammals and method for treating a patient suffering from sick conditions.
CA2062973A1 (en) Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
BR9806060A (en) Compound, pharmaceutical composition and processes to treat a patient suffering from a sick condition, to inhibit factor xa, and to inhibit thrombin formation.
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
CA2227205A1 (en) Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
GR3033828T3 (en) Substituted biphenyl compounds for the treatment of inflammation
SI1624878T1 (en) Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
NO950275L (en) Combination therapy for osteoporosis
Jackson Jr et al. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer
DK0735877T3 (en) 6- (2-imidazolinylamino) quinoxaline compounds suitable as alpha-2-adrenoceptor agonists.
BR0112364A (en) Combinations of bisphosphonates, estrogens and optionally estrogens
BR9813996A (en) 2-arylbenzo [b] thiophenes useful for the treatment of estrogen deprivation syndrome
DE3364588D1 (en) Fungicidal agent
BR0101161A (en) Developing composition and heat-sensitive recording material
BR0212583A (en) I agonists for alkyl urea retinoids
Parkinson et al. Cytochrome P-450-mediated metabolism of biphenyl and the 4-halobiphenyls
Von Burg et al. Biliary mobilization of cadmium by 2, 3‐dimercaptopropanol and some related compounds
WO2000016712A3 (en) Calcified tissue facing preparation containing an antimicrobial agent
CA2440214A1 (en) Method of modulating the proliferation of medullary thyroid carcinoma cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed